Stifel Nicolaus analyst Stephen Willey has maintained their bullish stance on ABEO stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Stephen Willey has given his Buy rating due to a combination of factors that highlight Abeona Therapeutics’ strategic advancements and promising outlook. The activation of the University of Texas Medical Branch as the fourth qualified treatment center (QTC) for Zevaskyn is a significant step, expanding patient access in Texas and the Gulf Coast region. This aligns with the company’s goal to increase treatment capacity and suggests a growing demand for Zevaskyn, which is expected to support future expansion plans.
Moreover, the recent initiation of the first commercial patient treatment at Stanford’s QTC marks a pivotal milestone, demonstrating the company’s operational progress and ability to meet patient needs. The management’s success in securing prior authorizations and the identification of numerous treatment-eligible patients further bolster confidence in achieving the projected patient treatment numbers for FY26. These developments, coupled with the increasing demand for Zevaskyn, underpin the positive outlook and justify the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.
ABEO’s price has also changed moderately for the past six months – from $6.220 to $5.520, which is a -11.25% drop .